Skip to main content

The context you need, when you need it

When news breaks, you need to understand what actually matters — and what to do about it. At Vox, our mission to help you make sense of the world has never been more vital. But we can’t do it on our own.

We rely on readers like you to fund our journalism. Will you support our work and become a Vox Member today?

Join now

Ellen Pao Plans to Appeal

With the filing, Pao buys some time to specify on exactly what grounds she will appeal.

Asa Mathat for Re/code

Ellen Pao filed a notice of appeal in San Francisco court on Monday, resurfacing the gender discrimination case she lost against former employer Kleiner Perkins Caufield & Byers in March.

With the filing, Pao buys some time to specify on exactly what grounds she will appeal. Heather Wilson, a spokeswoman for Pao, said she had no comment, but confirmed Pao is represented by the same legal team, Alan Exelrod and Therese Lawless.

Christina Lee, a spokeswoman for the venture capital firm Kleiner Perkins, said in an emailed statement, “A 12-member jury found decisively in favor of KPCB on all four claims. We remain committed to gender diversity in the workplace and believe that women in technology would be best served by focusing on this issue outside of continued litigation.”

After a five-week trial that sparked a larger discussion about workplace gender issues, a jury ruled against Pao on all counts in the case, which charged that she was fired — and not promoted — because of her gender and because she complained about her treatment.

Pao appealed before the deadline of June 8, and today’s filing gives her at least 40 days to establish what exactly her complaint will be. Employment lawyers and court watchers had noted Judge Harold Kahn attempted to make the jury’s decision airtight by largely rejecting the Kleiner legal team’s objections and procedural requests throughout the trial. However, it’s also possible Pao could try to return to some pre-trial rulings that restricted access to information about the performance of other Kleiner Perkins employees, both women and men, as well as the time period that could be discussed in front of the jury.

Last Wednesday, Pao spoke at Re/code’s Code Conference in Rancho Palos Verdes, Calif. She said onstage that she “didn’t plan on being a symbol” and that the lawsuit was more about telling her side of the story.

In April, Kleiner Perkins offered let Pao off the hook for some $1 million in fees associated with its defense effort, but only if Pao did not appeal. In response, Pao’s team described the costs as excessive.

This article originally appeared on Recode.net.

See More:

More in Technology

Podcasts
Are humanoid robots all hype?Are humanoid robots all hype?
Podcast
Podcasts

AI is making them better — but they’re not going to be doing your chores anytime soon.

By Avishay Artsy and Sean Rameswaram
Future Perfect
The old tech that could help stop the next airborne pandemicThe old tech that could help stop the next airborne pandemic
Future Perfect

Glycol vapors, explained.

By Shayna Korol
Future Perfect
Elon Musk could lose his case against OpenAI — and still get what he wantsElon Musk could lose his case against OpenAI — and still get what he wants
Future Perfect

It’s not about who wins. It’s about the dirty laundry you air along the way.

By Sara Herschander
Life
Why banning kids from AI isn’t the answerWhy banning kids from AI isn’t the answer
Life

What kids really need in the age of artificial intelligence.

By Anna North
Culture
Anthropic owes authors $1.5B for pirating work — but the claims process is a Kafkaesque messAnthropic owes authors $1.5B for pirating work — but the claims process is a Kafkaesque mess
Culture

“Your AI monster ate all our work. Now you’re trying to pay us off with this piece of garbage that doesn’t work.”

By Constance Grady
Future Perfect
Some deaf children are hearing again because of a new gene therapySome deaf children are hearing again because of a new gene therapy
Future Perfect

A medical field that almost died is quietly fixing one disease at a time.

By Bryan Walsh